Who owns TSCAN THERAPEUTICS INC?
- Ticker: TCRX
- CUSIP Number: 89854m101
Tip: Access positions for across all investors
Analyze quarterly positions in Tscan Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Tscan Therapeutics stock
Who bought or sold TSCAN THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Lynx1 Capital Management | 5.2M | $26M | 0% | Sep 2024 |
|
| EcoR1 Capital | 5.0M | $29M | 0% | Jun 2024 |
|
| BlackRock | 4.6M | $23M | 100% | Sep 2024 |
|
| BlackRock | 4.5M | $26M | 163% | Jun 2024 |
|
| BVF | 3.0M | $15M | 0% | Sep 2024 |
|
| Baker Bros. Advisors | 2.8M | $14M | 0% | Sep 2024 |
|
| Vanguard Group | 2.1M | $13M | 18% | Jun 2024 |
|
| Propel Bio Management | 2.1M | $12M | 0% | Jun 2024 |
|
| Deer Management | 1.2M | $6.2M | 0% | Sep 2024 |
|
| Alphabet | 1.1M | $5.4M | 0% | Sep 2024 |
|
| Simplify Asset Management | 1.0M | $5.2M | 0% | Sep 2024 |
|
| Dr. Jeffrey R. Jay, M.D. | 1.0M | $5.1M | 8% | Sep 2024 |
|
| Geode Capital Management | 974k | $4.8M | 8% | Sep 2024 |
|
| Stempoint Capital | 861k | $4.3M | 2% | Sep 2024 |
|
| DC Funds | 630k | $3.7M | 0% | Jun 2024 |
|
| State Street Corporation | 608k | $3.6M | 350% | Jun 2024 |
|
| Standard Life Aberdeen | 372k | $1.9M | 27% | Sep 2024 |
|
| Northern Trust | 324k | $1.6M | 321% | Sep 2024 |
|
| Morgan Stanley | 242k | $1.4M | 8% | Jun 2024 |
|
| Tocqueville Asset Management | 206k | $1.0M | -2% | Sep 2024 |
|
| Marshall Wace | 165k | $823k | -46% | Sep 2024 |
|
| Alpine Partners VI | 138k | $804k | 100% | Jun 2024 |
|
| Dimensional Fund Advisors | 134k | $669k | 1030% | Sep 2024 |
|
| Charles Schwab Investment Management | 113k | $562k | 0% | Sep 2024 |
|
| Woodline Partners | 109k | $541k | -34% | Sep 2024 |
|
| Jacobs Levy Equity Management | 103k | $515k | 100% | Sep 2024 |
|
| Bank of America Corporation | 97k | $484k | 122% | Sep 2024 |
|
| Stifel Financial | 95k | $558k | -6% | Jun 2024 |
|
| Jane Street | 94k | $468k | -5% | Sep 2024 |
|
| NewEdge Wealth | 92k | $456k | 0% | Sep 2024 |
|
| Bank of New York Mellon | 88k | $440k | -24% | Sep 2024 |
|
| Qube Research & Technologies | 78k | $459k | -45% | Jun 2024 |
|
| Brown Brothers Harriman & Co. | 76k | $445k | 100% | Jun 2024 |
|
| Renaissance Technologies | 74k | $369k | -8% | Sep 2024 |
|
| LMR Partners | 72k | $358k | -89% | Sep 2024 |
|
| Nuveen Asset Management | 70k | $409k | 100% | Jun 2024 |
|
| Barclays | 58k | $289k | 341% | Sep 2024 |
|
| ExodusPoint Capital Management | 56k | $278k | 57% | Sep 2024 |
|
| Troluce Capital Advisors | 53k | $264k | -43% | Sep 2024 |
|
| Rhumbline Advisers | 47k | $235k | 1% | Sep 2024 |
|
| Pale Fire Capital SE | 44k | $218k | 103% | Sep 2024 |
|
| Bridgeway Capital Management | 38k | $224k | -39% | Jun 2024 |
|
| Dean Capital Investments Management | 36k | $208k | 0% | Jun 2024 |
|
| Goldman Sachs Group | 35k | $206k | -86% | Jun 2024 |
|
| Cubist Systematic Strategies | 32k | $160k | 100% | Sep 2024 |
|
| Jpmorgan Chase & Co | 32k | $158k | 94% | Sep 2024 |
|
| Citigroup | 28k | $138k | 229% | Sep 2024 |
|
| MetLife Investment Advisors | 23k | $116k | 129% | Sep 2024 |
|
| Mirae Asset Global Etfs Holdings | 21k | $106k | 100% | Sep 2024 |
|
| Letko, Brosseau & Associates | 21k | $103k | 0% | Sep 2024 |
|
| Deutsche Bank Aktiengesellschaft | 21k | $103k | 0% | Sep 2024 |
|
| EntryPoint Capital | 21k | $103k | 100% | Sep 2024 |
|
| Squarepoint Ops | 19k | $113k | 100% | Jun 2024 |
|
| Invesco | 18k | $90k | -96% | Sep 2024 |
|
| SG Americas Securities | 16k | $78k | 100% | Sep 2024 |
|
| Manufacturers Life Insurance Company | 15k | $90k | 100% | Jun 2024 |
|
| Ing Investment Management | 14k | $69k | 2% | Sep 2024 |
|
| Wells Fargo & Company | 14k | $69k | 0% | Sep 2024 |
|
| AQR Capital Management | 13k | $64k | 100% | Sep 2024 |
|
| Royal Bank of Canada | 12k | $66k | 242% | Sep 2024 |
|
| T. Rowe Price Associates | 12k | $62k | 0% | Sep 2024 |
|
| Advisor Group Holdings | 12k | $61k | 100% | Sep 2024 |
|
| CornerCap Investment Counsel | 11k | $54k | -53% | Sep 2024 |
|
| Susquehanna International | 10k | $51k | 100% | Sep 2024 |
|
| Waldron | 10k | $50k | 0% | Sep 2024 |
|
| Aries Wealth Management | 10k | $50k | 0% | Sep 2024 |
|
| New York State Common Retirement Fund | 6.2k | $31k | -69% | Sep 2024 |
|
| Us Bancorp | 4.5k | $22k | 100% | Sep 2024 |
|
| Tower Research Capital | 4.2k | $25k | 100% | Jun 2024 |
|
| Summit Investment Advisors | 3.8k | $19k | 0% | Sep 2024 |
|
| California State Teachers Retirement System | 2.8k | $14k | 0% | Sep 2024 |
|
| Amalgamated Bank | 1.3k | $7.0k | 0% | Sep 2024 |
|
| GAMMA Investing | 142.00 | $707.003800 | 100% | Sep 2024 |
|
| NISA Investment Advisors | 121.00 | $603.003500 | 100% | Sep 2024 |
|
| Lazard Asset Management | 70.00 | $0 | -60% | Sep 2024 |
|
| Sterling Capital Management | 68.00 | $339.000400 | 100% | Sep 2024 |
|
| Atlas Capital Advisors | 18.00 | $88.999200 | 0% | Sep 2024 |
|
| CWM | 7.00 | $0 | 100% | Sep 2024 |
|
| Capital Advisors | 2.00 | $0 | 100% | Sep 2024 |
|
Who sold out of Tscan Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Paradigm Biocapital Advisors | Jun 2024 | 354k | $2.1M |
| Citadel Advisors | Jun 2024 | 158k | $924k |
| Laurion Capital Management | Jun 2024 | 60k | $353k |
| American Century Companies | Jun 2024 | 48k | $278k |
| Balyasny Asset Management | Mar 2024 | 42k | $333k |
| Two Sigma Investments | Mar 2024 | 38k | $300k |
| Millennium Management | Jun 2024 | 28k | $163k |
| Man Group | Jun 2024 | 19k | $109k |
| OMERS Administration Corporation | Mar 2024 | 14k | $113k |
| Marathon Trading Investment Management | Jun 2024 | 14k | $80k |
| Leucadia National Corporation | Mar 2024 | 12k | $97k |
| Privium Fund Management | Jun 2024 | 12k | $69k |
| Jump Financial | Jun 2024 | 11k | $63k |
| Macquarie Group | Mar 2024 | 1.6k | $12.944000 |